Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "company"

4867 News Found

Senores Pharma forms new subsidiary in US
News | November 06, 2025

Senores Pharma forms new subsidiary in US

Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals


Zydus wellness reports 31% growth in net sales in Q2 FY26
News | November 06, 2025

Zydus wellness reports 31% growth in net sales in Q2 FY26

During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries


Cupid bags largest share in South Africa’s 5-year National Condom Program
News | November 06, 2025

Cupid bags largest share in South Africa’s 5-year National Condom Program

Cupid has been allocated approximately 23.4 million units of female condoms per year


Ginkgo Bioworks and Bayer renew partnership to power the next wave of Ag Biologicals
News | November 06, 2025

Ginkgo Bioworks and Bayer renew partnership to power the next wave of Ag Biologicals

Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform


Sumitomo Pharma America unveils promising new leukemia and myelofibrosis data ahead of ASH 2025
Clinical Trials | November 06, 2025

Sumitomo Pharma America unveils promising new leukemia and myelofibrosis data ahead of ASH 2025

Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis


RedHill secures final $10.5M court judgment for enforcement
Biopharma | November 06, 2025

RedHill secures final $10.5M court judgment for enforcement

RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment


J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial
News | November 06, 2025

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year


FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency
Drug Approval | November 06, 2025

FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency

Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA


Teva reports 11th consecutive quarter of growth
News | November 06, 2025

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.